GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » PS Ratio

Rhythm Pharmaceuticals (Rhythm Pharmaceuticals) PS Ratio : 32.77 (As of May. 06, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rhythm Pharmaceuticals's share price is $43.85. Rhythm Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.34. Hence, Rhythm Pharmaceuticals's PS Ratio for today is 32.77.

The historical rank and industry rank for Rhythm Pharmaceuticals's PS Ratio or its related term are showing as below:

RYTM' s PS Ratio Range Over the Past 10 Years
Min: 16.17   Med: 66.45   Max: 22550
Current: 32.81

During the past 9 years, Rhythm Pharmaceuticals's highest PS Ratio was 22550.00. The lowest was 16.17. And the median was 66.45.

RYTM's PS Ratio is ranked worse than
73.59% of 996 companies
in the Biotechnology industry
Industry Median: 9.145 vs RYTM: 32.81

Rhythm Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.41. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.34.

During the past 12 months, the average Revenue per Share Growth Rate of Rhythm Pharmaceuticals was 195.80% per year.

Back to Basics: PS Ratio


Rhythm Pharmaceuticals PS Ratio Historical Data

The historical data trend for Rhythm Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals PS Ratio Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only - - 155.94 64.14 34.23

Rhythm Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.14 28.73 21.17 21.13 34.23

Competitive Comparison of Rhythm Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Rhythm Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's PS Ratio falls into.



Rhythm Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Rhythm Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=43.85/1.338
=32.77

Rhythm Pharmaceuticals's Share Price of today is $43.85.
Rhythm Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Rhythm Pharmaceuticals  (NAS:RYTM) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Rhythm Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals (Rhythm Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
Executives
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116